Ocular Therapeutix

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™. Ocular Therapeutix has built a robust product pipeline of drug delivery solutions developed to reduce the complexity and burden of the current standard of care and position itself to become a leader in the ophthalmic space.

Ocular Therapeutix has a commercially available drug product, DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use. DEXTENZA is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and for the treatment of ocular itching associated with allergic conjunctivitis; the product is currently being marketed through a fully integrated specialty sales force. Ocular Therapeutix’s lead clinical program OTX-TKI* (axitinib intravitreal implant), is currently being developed to treat wet AMD and diabetic retinopathy; other indications may also be pursued in due course. Other clinical programs include OTX-TIC (travoprost intracameral implant), for intracameral injection, for the treatment of elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for intracanalicular use, for the chronic treatment of dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for intracanalicular use, for the short-term treatment of the signs and symptoms of dry eye disease.

At Ocular Therapeutix, we strive to build a strong and collaborative culture where employees can flourish professionally and achieve their career goals. We encourage out of the box thinking, creativity and cross-functional collaborative engagement throughout the organization.

Corporate Highlights

Transforming Current Standard of Care

With sustained-release therapies using our proprietary hydrogel platform

Developing Pipeline with Multi-Stage Product Candidates

Diversified across several therapeutic areas in ophthalmology

Protecting Innovation

Ocular products are protected by solid IP, technical know-how, and NDA regulatory applications that help preserve exclusivity for extended periods of time

Evolving to Partnership Mindset

To maximize value of pipeline and enable new collaborations

Targeting Large Market Opportunities

With addressable market of $24B in estimated global sales1-3 

REFERENCES: 1. 2023 Retinal Pharmaceuticals Market Report. Market Scope. 2. 2023 Glaucoma Pharmaceuticals Market Report. Market Scope. 3. 2022 Dry Eye Products Market Report. Market Scope.

*AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI

†PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC

‡These data reflect the total global market for the respective indications. Our market opportunity for such indications reflects a portion of this market